Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Contezolid Acefosamil/Contezolid vs Linezolid in Diabetic Foot Infections
2022-500257-16-00Phase 3Authorised
- Sponsor
- MicuRx Pharmaceuticals
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of contezolid in diabetic foot infection (DFI) (2 arms), sponsored by MicuRx Pharmaceuticals. Primary endpoints: Investigator-assessed clinical response at Day 35 (MITT) and Safety and tolerability. Planned start Mar 2023; status: authorised.
02
Drugs
contezolid
03
Conditions
diabetic foot infection (DFI)
Beyond the preview
Go deeper on 2022-500257-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500257-16-00.